Kornimate/medical-research-clean huggingface dataset:
outcomes following anterior approach to total hip arthroplasty

Conditions: Osteoarthritis, Hip

Summary: osteoarthritis disables approximately 10% of people who are 60 years or older and compromises the quality of life of more than 20 million americans every year. osteoarthritis is caused by the breakdown of cartilage that lines the bones at your joints from daily wear and tear and results in pain and restricted function. total hip arthroplasty (tha) or total hip replacement, is currently one of the most successful and cost-effective treatments used to eliminate pain and restore function in those suffering from osteoarthritis. there are multiple ways to perform a tha. the main difference between each type is the point of incision in relation to a muscle on the outer surface of your hip bone: gluteus medius. the incision performed can be anterior (in front of the muscle), anterolateral (in front and to the side of the muscle), or posterior (from the back). each of these approaches has its own advantages and disadvantages, but there is no evidence available that makes one better than the other. the purpose of this study is to determine which of the three approaches to tha is the most effective. the main outcome that will determine the most effective approach is the functional ability of the patients included in this study at 52 weeks. the investigators will also compare whether the patient's: length of hospital stay, use of assistive devices, need for revision surgery, ability to return to work, ability to relieve pain, complication rate, and quality of life. the investigators hypothesize that the anterior approach will be the most effective approach in reducing the rate of post-operative complications after tha.


Eligibility criteria:
inclusion criteria: 1. men or women who are 18 years of age or older. 2. primary diagnosis of hip arthritis (radiographically and clinically). 3. patients undergoing an unilateral tha. 4. provision of informed consent by patient. exclusion criteria: 1. patients being managed with alternative approaches (other than anterior, anterolateral or posterior tha) will be excluded. 2. patients undergoing a revision tha. 3. patients undergoing a bilateral tha. 4. patients with infection around the hip (soft tissue or bone). 5. patients who have had previous major hip surgery (hip arthroscopy is permitted) or hardware implanted in their hip. 6. patients who are currently enrolled in another surgical intervention trial. 7. patient has cognitive or language barriers that would limit completion of quality of life, pain, and function questionnaires in english. 8. anticipated problems, in the judgment of the investigators, with maintaining follow-up. we will, for example, exclude patients with no fixed address, those who report a plan to move out of town in the next year, or intellectually challenged patients without adequate family support.

Keywords: primary osteoarthritis, hip total hip arthroplasty anterior approach posterior approach anterolateral approach cohort study outcomes, complication rate outcomes, quality of life
consortium on risk for early-onset parkinson's disease (core pd)

Conditions: Parkinson's Disease

Summary: the purpose of this study is to investigate genetic and environmental risk factors that increase susceptibility to the development of early-onset parkinson's disease (developed at or before age 50).

parkinson's disease (pd) is a common, neurodegenerative condition. although mostly a late-onset disorder, 10 percent of people with pd are reported to develop symptoms before the age of 50. to date, six genes have been found to be associated with pd, however the majority have been found in rare pd 'families'. some studies have also identified a number of environmental risk factors, such as pesticide use, that appear to increase the risk of pd. in a previous study, dr. karen marder and her research team found that close family members of people with both early- and late-onset pd have a three-fold increased risk of pd compared to close family members of people without pd. the purpose of the consortium on risk for early-onset parkinson's disease (core pd) study is to identify the genetic factors that contribute to the development of early-onset parkinson's disease, and to understand how these genetic factors interact with other genes and the environment to cause pd. participation in the study involves a blood draw (to look for genetic factors associated with pd), questionnaires collecting information on family and medical history, and a neurological examination. in addition participants may be contacted in the future and asked to participate in a more detailed interview. at that time, study investigators will also ask participants for permission to contact family members to invite them to participate in the study. this research study requires participants to sign a consent form, which states that the research is voluntary and confidential. in addition, since this is a research study, genetic results are not released to participants or their family members now or in the future. scientists hope this multi-center study will increase the current knowledge of pd and that the identification of factors that cause pd will lead to better diagnosis and treatment.

Eligibility criteria:
inclusion criteria: * any person with parkinson's disease in the united states * symptoms occurred before the age of 50 * diagnosed by a neurologist. exclusion criteria: * children who are \<18 years of age * any probands who are cognitively impaired

Keywords: parkinson's disease pd gene environment early-onset parkinson's disease
a study of plasmatic concentrations of endothelin-1 (et1), atrial natriuretic peptide (anp) and brain natriuretic peptide (bnp) in acute ischemic stroke.

Conditions: Stroke

Summary: a study of plasmatic concentrations of endothelin-1 (et1), atrial natriuretic peptide (anp) and brain natriuretic peptide (bnp) in acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * male or female * age \> 18 * with an ischemic stroke exclusion criteria: * cardiac failure * renal failure

Keywords: areet1 anp bnp pronostic markers of stroke
the study for evaluating the clinical effectiveness and safety of respiratory rehabilitation software 'redpill breath'(copd, asthma, lung cancer, etc.)

Conditions: Respiratory System Disease; Chronic Obstructive Pulmonary Disease; Asthma Copd; Lung Cancer; Lung Diseases; Pulmonary Rehabilitation; Respiratory Rehabilitation; Home Based Rehabilitation; Mobile Application; Rehabilitation

Summary: the purpose of the study is to prove the clinical superiority of respiratory rehabilitation software "redpill breath" and evaluate the clinical improvement effect by 6-minute walk test of the software, compared to the manual rehabilitation management for those who need respiratory rehabilitation(copd, asthma, lung cancer, etc.)


Eligibility criteria:
inclusion criteria: 1. 19 to 80 years-old 2. subject who has difficulty in respiratory symptoms and routine with the criteria as below 1) mmrc(modified medical research council dyspnea scale) 1 point at least 2) in accordance with pulmonary function test(pft/let/eeg) examined, if there is in one of the following cases as below \[a lung cancer patient\] (fvc or fev1 \< 80%), \[no lung cancer patient\] (post-bronchodilator fev1/fvc \< 0.7) and (post-bronchodilator fev1 \< 80%) 3. subject with an android smartphone (os 8.0 or higher, internal memory (hdd) of 32gb or higher) or iphone (ios 13.0 or higher, internal memory (hdd of 32gb or higher) 4. subject who can use effectively smartphone and mobile software 5. subject who brings their smartphone for a walking test during 12 weeks of the clinical trial. 6. subject who makes the decision voluntarily for participating in the clinical trial and to write their signature to the consent of subject's explanation. 7. subject who complies with the clinical protocol exclusion criteria: 1. subject who has respiratory distress syndrome, caused by a kind of neuromuscular disease, spinal cord injury, thoracic deformation, etc. 2. subject who participate in respiratory rehabilitation treatment within 6 months of the screening date 3. subject who undergoes respiratory-related symptoms deteriorate within 2 weeks of the screening date to the point where they need additional antibiotics or steroids 4. subject who has an unstable cardiovascular disease (unstable angina pectoris, acute myocardial infarction, severe coarctation of aorta, etc.) 5. a pulmonary arterial hypertension subject 6. subject prescribed physical(e.g. lower-leg joint surgery, neurological limitation) or cognitive factors(e.g. psychical disorder) 7. pregnant or lactating women 8. subject who is unable to read text and tough to communicate 9. subject who has participated in other clinical trials within 90 days of the screening date or participating in other clinical trials. 10. subject who is determined to inappropriate to perform this study according to clinical research associate's opinion(e.g if someone has a bearing on the result of the clinical trial ethically or clinically)

Keywords: dtx digital therapeutics pr copd
a study of safety and drug levels of hib210 in healthy volunteers

Conditions: Immune System Diseases; Autoimmunity

Summary: the goal of this clinical trial is to test safety of the investigational product in healthy volunteers. the main questions it aims to answer is when hib210 is administered as multiple doses, is it: 1. safe 2. well tolerated 3. does the body absorb and eliminate hib210 as expected

study sponsor, originally hi-bio, inc., is now hi-bio, a biogen company.

Eligibility criteria:
key eligibility criteria: * healthy male and females between 19 to 65 years of age * normal or not significantly abnormal laboratory tests and ekg findings during screening * no significant medical conditions that might affect ability to participate in the study or present a safety risk * no evidence of significant or recurrent infection or recent infection * no history of cancer other than certain skin cancers and limited cancer of the cervix of the womb * willingness to comply with birth control requirements of the study (for both men and women) * no recent major surgery or trauma or planned surgery during the study or within 1 month after the study * body mass index (bmi) between 18 and 32 kg/m2

Keywords: c5ar1 c5a receptor c5ar1 inhibition cd88
composite repair using silane coupling agent

Conditions: Tooth Discoloration; Hypersensitivity; Tooth Fracture; Dental Restoration Failure of Marginal Integrity

Summary: evaluation the influence of the use of silane coupling agent application as a separate step versus application of silane or acid resistance silane containing adhesives on the clinical performance of repaired posterior resin composite restorations according to modified united states public health service (usphs) criteria over one year.

some manufacturers have produced silane-containing adhesives in their new products, which might eliminate the need to apply separate silane. however, this silane coupling agent can be hydrolyzed by the acidic monomer in the adhesive making it useless. acid resistance silane containing adhesive is the update version of the silane containing adhesive which provides a long lasting effective bond between the old and new resin composite restorations

Eligibility criteria:
inclusion criteria: * participants inclusion: patients aging (18-45). patients with a high level of oral hygiene. patients with good likelihood of recall availability. - teeth inclusion: the restorations were first placed 12 to 24 months ago. teeth with healthy remaining tooth structure. posterior restorations with approximately 3mm in size occlusal marginal defect. asymptomatic teeth before repair. exclusion criteria: * participants exclusion: patient with high caries risk patient with poor periodontal health. heavy bruxism habits. pregnant or lactating females. -teeth exclusion: the restorations with large defects the restorations in the third molars last experience with allergic reactions against any components of the used materials. patients receiving orthodontic treatment

Keywords: silane coupling agent adhesive containing silane acid resistance silane containing adhesive. defective resin composite restoration repair of posterior resin composite
the effect of hyperoxia and hypoxia on fluorescence lifetime imaging ophthalmoscopy in healthy subjects- a randomized, double blind, crossover study

Conditions: To Investigate the Effect of 100% Oxygen Breathing on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Healthy Subjects

Summary: the present study aims to investigate whether flio can also detect shorttime changes in retinal metabolism induced by hyperoxia and hypoxia. for this purpose, 48 healthy subjects will be included in the present study and changes in flio will be assessed during breathing of 100% oxygen to induce hyperoxia as well as during breathing of 12% oxygen in nitrogen to induce hypoxia. since stimulation with flickering light also induces a higher metabolic demand in the retina (functional hyperemia), thisprovocation test will also applied during breathing of the different gas mixtures and compared to baseline. to gain information about retinal blood flow, optical coherence tomography angiography (oct-a) will be performed. the results of the present study can help to gain more insight into the physiology of the retinal metabolism and might give grounds to establish new biomarkers in future studies.


Eligibility criteria:
inclusion criteria: * men and women aged between 18 and 35 years * normal ophthalmic findings * ametropia ≤ 6 diopters * normal findings in the medical history and physical examination including ecg unless the investigator considers an abnormality to be clinically irrelevant * nonsmokers exclusion criteria: regular use of medication, abuse of alcoholic beverages or drugs * participation in a clinical trial in the 3 weeks preceding the study * treatment in the previous 3 weeks with any drug (except contraceptives) * symptoms of a clinically relevant illness in the 3 weeks before the first study day * blood donation during the previous 3 weeks * history or family history of epilepsy * pregnant or breast-feeding women * women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception
reliability and validity of turkish version of the diabetes education questionnaire (date-q)

Conditions: Diabetes Mellitus

Summary: the diabetes education questionnaire (date-q) is a questionnaire that includes comprehensive care components of diabetes management and specifically questions the effect of exercise on blood glucose levels and the knowledge of the correct exercise intensity in patients with diabetes. it can be easily and rapidly applied. the aim of this study is to evaluate the translation into turkish, validity and reliability of the date-q, which questions the knowledge of diabetic patients about their disease.


Eligibility criteria:
inclusion criteria: . age of 18 or above * those whose native language is turkish * volunteer to participate in the study exclusion criteria: * individuals who cannot cooperate (those who score below 24 points according to the standardized mini mental test) * those who have problems understanding and speaking turkish * any visual or cognitive disorder that would prevent the participant from answering the survey
efficacy of intensive cervical traction on depression, insomnia, quality of life in patients with cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: cervical radiculopathy is a common and disabling condition involving local pain in the neck region and pain that radiates into the upper limb. recent data suggest that cervical traction may effectively reduce disability and pain, with a dose-response relationship. the main aim of this study was therefore to evaluate the effect of an intensive cervical traction protocol for patients with cervical radiculopathy on depression, insomnia, and quality of life (1).

the investigators will conduct a prospective open observational study of thirty-six patients referred by their neurosurgeons for symptoms suggestive of cervical radiculopathy. all patients undergo the same treatment: a 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. the main objective will be the evaluation of depression, insomnia, and quality of life. the investigators will evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life. the primary outcomes will be hospital anxiety and depression scale (hads) and short form 36 health survey (sf-36) before and after treatment with spinal traction. thirty-five healthy controls, matched with patients for age and sex, completed the same questionnaires. traction was added to patients' medications which were not enough to control patients' symptoms and did not change during traction. depressive and anxiety symptoms were assessed by an arabic version of hospital anxiety and depression scale. health-related quality of life was assessed by applying the arabic version of the short-form 36 health survey (sf-36) \[ insomnia severity index will be used to evaluate insomnia.

Eligibility criteria:
inclusion criteria: * patients with prolapsed cervical disc were diagnosed based on clinical examination and mri cervical spine * patients showed only some improvement on medical treatment, nsai drugs, muscle relaxants, and drugs for neuropathic pain, which will continue and will not change during spinal traction exclusion criteria: * in addition to non-consenting patients, patients with the following conditions will be excluded from the present study: ligamentous instability, osteomyelitis, diskitis, primary or metastatic spinal cord tumor, severe osteoporosis, myelopathy, fibromyalgia, or untreated hypertension. * patients currently treated for psychiatric disorders, or those who had past history of psychiatric disorders, will also excluded

Keywords: cervical traction depression insomnia quality of life
risk factors and biomarkers for diagnosis and treatment of eoe

Conditions: Eosinophilic Esophagitis

Summary: purpose: to validate our previously developed model of risk factors for diagnosis of eosinophilic esophagitis (eoe), and to assess the utility of serum levels of biomarkers in diagnosis and monitoring of treatment of eoe. participants: up to a total of 800 participants (approximately 400 with eoe and 400 without eoe) who are referred for upper endoscopy. procedures: this is a prospective cohort study. patients will be compared with newly diagnosed eoe to non-eoe controls, obtain baseline measures, reassess eoe patients after treatment, and also reassess untreated controls. data collection will include questionnaire results, blood collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). blood will be analyzed for the presence of the candidate biomarkers. patients will be compared with newly diagnosed eoe to non-eoe controls, obtain baseline measures, reassess eoe patients after treatment, and also reassess untreated controls. data collection will include questionnaire results, blood collection, possible saliva collection, possible urine collection, and tissue collection (esophageal biopsies performed during upper endoscopy per pre-specified protocol). blood will be analyzed for the presence of the candidate biomarkers, including eotaxin-3 and il-13.


Eligibility criteria:
inclusion criteria: 1. referral for upper endoscopy (esophagogastroduodenoscopy; egd) to evaluate specific symptoms (dysphagia, heartburn, reflux, chest pain, regurgitation, abdominal pain, nausea, or vomiting). 2. age 18 or older exclusion criteria: 1. acute gi bleeding. 2. known cancer of the esophagus, stomach, or small bowel. 3. prior esophageal resection. 4. esophageal varices. 5. active anticoagulation or bleeding diathesis. 6. medical instability (determined by the performing endoscopist) to precludes performing egd. 7. pregnancy 8. inability to read or understand the consent form and questionnaire.

Keywords: esophagitis eosinophilic esophagitis esophageal diseases gastrointestinal diseases digestive system diseases
cardiac arrest in residential areas with mobile first-responder activation

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the study aims to increase proportions of bystander defibrillation during out-of-hospital cardiac arrest (hereof referred to as cardiac arrest) in residential areas with a high density of cardiac arrests. the intervention consists of automated external defibrillators (aeds) and residents' involvement in resuscitation through training and enrollment as citizen responders.

survival decreases by 10% for every minute that passes after a cardiac arrest until defibrillation. despite an increasing number of available aeds, survival and defibrillation rates in residential areas remain poor. efforts to increase bystander defibrillation has the potential to improve survival. through the strategic deployment of aeds, training, and recruitment of residents as citizen responders, we aim to improve proportions of bystander defibrillation and 30-day survival in densely populated residential areas with a high density of cardiac arrests.

Eligibility criteria:
inclusion criteria: * all witnessed cardiac arrests recognized registered in the danish cardiac arrest registry occurring within the study sites. this excludes non witnessed cardiac arrests. * witnessed cardiac arrest * non-traumatic etiology, this excludes intoxication, drowning or suicide. exclusion criteria: * cardiac arrest occurring in a nursing home * cardiac arrest not treated by the ems due to ethical reasons or obvious signs of death * not true cardiac arrest (suspected, but not verified) * cardiac arrests witnessed by the emergency medical personnel

Keywords: suddan cardiac arrest heart arrest heart diseases cardiovascular diseases
efficacy and safety of ginkgo biloba extract in mild cognitive impairment and cerebrovascular insufficiency

Conditions: Mild Cognitive Impairment; Cerebrovascular Insufficiency

Summary: the purpose of the study is to determine weather ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

inclusion criteria is cerebrovascular insufficiency mnse\>20. 90 patients are divided into three groups randomly. first group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. methods used for evaluation are scag, mmse, mdrs, vft, cgi, tcd and color doppler of carotid arteries. methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ecg.

Eligibility criteria:
inclusion criteria: * cerebrovascular insufficiency and mild cognitive disorder (mmse=20-28) exclusion criteria: * pregnancy * cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder * alcohol or drug abuse

Keywords: ginkgo biloba cerebrovascular insufficiency mild cognitive impairment concentration impairment